ArticleCardiology research and practice2022
Effect of Lycopene Supplementation on Some Cardiovascular Risk Factors and Markers of Endothelial Function in Iranian Patients with Ischemic Heart Failure: A Randomized Clinical Trial.
Article in Cardiology research and practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Dietary strategies and nutritional supplements in the management of heart failure: a systematic review.Frontiers in nutrition · 2024Pooled it
- Tomato-Derived Lycopene: From Phytochemistry and Extraction Technologies to Bioavailability and Nutraceutical Applications.Molecules (Basel, Switzerland) · 2026Review
- Preliminary Quality and Safety Evaluation of Lycopene-Based Dietary Supplements: Analysis of Active Compound Content, Microbiological Purity, and Chemical Contaminants.Foods (Basel, Switzerland) · 2026Article
- Modulation of Redox Balance by Phytochemicals: Implications for Cardiovascular Health.Nutrients · 2026Review
- Synergy Between Lycopene and Food Components: a Review on the Mechanisms and Health Effects.Plant foods for human nutrition (Dordrecht, Netherlands) · 2025Review
- Chromatic symphony of fleshy fruits: functions, biosynthesis and metabolic engineering of bioactive compounds.Molecular horticulture · 2025Review
- Lycopene: A Potent Antioxidant with Multiple Health Benefits.Journal of nutrition and metabolism · 2024Review
- Association between ischemic heart disease and dietary intake of lycopene: a case-control study.Frontiers in nutrition · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study aimed to explore if supplementary lycopene tablets may help heart failure (HF) patients improve their lipid profile, BP, and the flow-mediated dilation (FMD) index for endothelial function. Methods: Fifty patients with ischemic HF with a reduced ejection fraction (HFrEF) were randomly assigned to one of two groups: the lycopene group which received 25 mg lycopene tablets once a day for 8 weeks and the control group which received placebo tablets containing starch once a day for 8 weeks. Results: Our results showed that after two months, the amount of triglyceride (TG) and FMD improved significantly compared to the control, TG decreased (219.27 vs. 234.24), and the mean of FMD increased (5.68 vs. 2.95). Other variables, including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density cholesterol (HDL-C), systolic blood pressure (SBP), and diastolic blood pressure (DBP), showed no improvement. Also, only SBP and FMD showed intragroup improvement in the intervention group. In the intervention group, only SBP and FMD exhibited intragroup improvement. Conclusions: It can be concluded that supplementing with lycopene can enhance endothelial function and reduce the TG levels in ischemic HFrEF patients. However, it had no positive effect on BP, TC, LDL-C, or HDL-C.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.